BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 29666026)

  • 1. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Minion LE; Tewari KS
    Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival with Cemiplimab in Recurrent Cervical Cancer.
    Tewari KS; Monk BJ; Vergote I; Miller A; de Melo AC; Kim HS; Kim YM; Lisyanskaya A; Samouëlian V; Lorusso D; Damian F; Chang CL; Gotovkin EA; Takahashi S; Ramone D; Pikiel J; Maćkowiak-Matejczyk B; Guerra Alía EM; Colombo N; Makarova Y; Rischin D; Lheureux S; Hasegawa K; Fujiwara K; Li J; Jamil S; Jankovic V; Chen CI; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Mathias M; Fury MG; Oaknin A;
    N Engl J Med; 2022 Feb; 386(6):544-555. PubMed ID: 35139273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
    Rischin D; Gil-Martin M; González-Martin A; Braña I; Hou JY; Cho D; Falchook GS; Formenti S; Jabbour S; Moore K; Naing A; Papadopoulos KP; Baranda J; Fury W; Feng M; Stankevich E; Li J; Yama-Dang NA; Yoo SY; Lowy I; Mathias M; Fury MG
    Gynecol Oncol; 2020 Nov; 159(2):322-328. PubMed ID: 32917410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Monk BJ; Sill MW; Burger RA; Gray HJ; Buekers TE; Roman LD
    J Clin Oncol; 2009 Mar; 27(7):1069-74. PubMed ID: 19139430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
    Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for the treatment of cervical cancer.
    Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
    Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
    Colombo N; Dubot C; Lorusso D; Caceres MV; Hasegawa K; Shapira-Frommer R; Tewari KS; Salman P; Hoyos Usta E; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Toker S; Li K; Keefe SM; Monk BJ;
    N Engl J Med; 2021 Nov; 385(20):1856-1867. PubMed ID: 34534429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
    Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
    JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
    Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
    BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.